Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Not Recruiting

Trial ID: NCT01163526,9,29,55,46552


A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment.

Official Title

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Stanford Investigator(s)

Samuel So, MD
Samuel So, MD

Lui Hac Minh Professor in the School of Medicine

John D. Louie, MD
John D. Louie, MD

Clinical Professor, Radiology

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine

Dominik Fleischmann
Dominik Fleischmann

Professor of Radiology (Cardiovascular Imaging)

Nishita Kothary, MD
Nishita Kothary, MD

Professor of Radiology (Interventional Radiology)


Inclusion Criteria:3.1.1 Patients with suspected or biopsy-proven liver masses including
unresectable hepatocellular carcinoma (HCC), unresectable colon cancer metastases to the
liver, and metastatic neuroendocrine tumors to the liver will be eligible for enrollment.

3.1.2 Patients who have undergone prior chemotherapy more than one year prior to the study
are eligible for enrollment.

3.1.4 Patients must be 18 years or older. Patients must not be pregnant and, if of
child-bearing age, must take precautions not to become pregnant.

3.1.5 No life expectancy restrictions.

3.1.6 ECOG and Karnofsky Performance Status will not be employed.

3.1.7 Patients with renal failure are ineligible for this study (Glomerular filtration rate
(GFR) must be > 60)

3.1.8 Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:3.2.1 Patients who have undergone prior chemoembolization of
hepatocellular carcinoma (HCC) are ineligible for enrollment. Patients who have undergone
chemotherapy within one year prior to the study are also ineligible for enrollment.

3.2.2 No restrictions regarding use of other investigational agents.

3.2.3 Patients with severe contrast allergy are ineligible.

3.2.4 Patients who are pregnant or are trying to become pregnant are excluded from this

3.2.5 Patients who are cancer survivors or Human Immunodeficiency Virus (HIV)-positive will
not be excluded.


procedure: CT perfusion

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Elizabeth Chitouras

New Trial Alerts

Receive email alerts when trials open to patients.